Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Alloway

Showing results (21-30 of 164) with videos related to

Pageof 17
Sort By:
Immunological Reviews|July 13, 2021
Plasma cell biology: Foundations for targeted therapeutic development in transplantationAmy P Rossi, Rita R Alloway, David Hildeman, et al.
Clinical Transplantation|December 17, 2010
Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studiesJohannes P van Hooff, Rita R Alloway, Pavel Trunečka, et al.
Transplantation Proceedings|June 15, 2004
One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumabR J Stratta, R R Alloway, A Lo, et al.
Transplantation Proceedings|June 15, 2004
Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipientsR J Stratta, R R Alloway, A Lo, et al.
Transplantation Proceedings|April 26, 2005
A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantationA Lo, R J Stratta, R R Alloway, et al.
Transplantation|June 9, 2001
The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipientsS Tuteja, R R Alloway, J A Johnson, et al.
Transplantation Proceedings|November 22, 2005
A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 yearsR J Stratta, R R Alloway, A Lo, et al.
Clinical Transplantation|October 15, 2013
A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patientsR D Bloom, J Trofe-Clark, A Wiland, et al.
Transplantation Proceedings|June 15, 2004
Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation?R J Stratta, R R Alloway, A Lo, et al.
Kidney International|February 17, 2012
Proteasome inhibitor-based therapy for antibody-mediated rejectionR Carlin Walsh, Rita R Alloway, Alin L Girnita, et al.
Pageof 17

Showing results (21-30 of 164) with videos related to

Sort By:
Pageof 17
Immunological Reviews|July 13, 2021
Plasma cell biology: Foundations for targeted therapeutic development in transplantationAmy P Rossi, Rita R Alloway, David Hildeman, et al.
Clinical Transplantation|December 17, 2010
Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studiesJohannes P van Hooff, Rita R Alloway, Pavel Trunečka, et al.
Transplantation Proceedings|June 15, 2004
One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumabR J Stratta, R R Alloway, A Lo, et al.
Transplantation Proceedings|June 15, 2004
Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipientsR J Stratta, R R Alloway, A Lo, et al.
Transplantation Proceedings|April 26, 2005
A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantationA Lo, R J Stratta, R R Alloway, et al.
Transplantation|June 9, 2001
The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipientsS Tuteja, R R Alloway, J A Johnson, et al.
Transplantation Proceedings|November 22, 2005
A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 yearsR J Stratta, R R Alloway, A Lo, et al.
Clinical Transplantation|October 15, 2013
A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patientsR D Bloom, J Trofe-Clark, A Wiland, et al.
Transplantation Proceedings|June 15, 2004
Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation?R J Stratta, R R Alloway, A Lo, et al.
Kidney International|February 17, 2012
Proteasome inhibitor-based therapy for antibody-mediated rejectionR Carlin Walsh, Rita R Alloway, Alin L Girnita, et al.
Pageof 17